- Rhinitis is defined as having two of the listed symptoms for ≥1 hour/day for ≥2 weeks
- blockage
- running (including postnasal drip)
- sneezing (including nasal itch)
- Classification is shown in the chart below
- Nasal problems are often multifactorial, this needs to be taken into account when using the classification or considering treatment
- Allergic rhinitis:
- is common and affects over 20% population every country
- is diagnosed by history and examination, and should be backed up by specific allergy tests where identification of specific triggers will enable avoidance or affect choice of treatment
- Non-allergic rhinitis:
- has a multifactorial aetiology
- if eosinophilic, usually responds to treatment with corticosteroids
- may be a presenting complaint for systemic disorders such as Wegener’s granulomatosis, Churg–Strauss syndrome and sarcoidoisis
- Infective rhinitis:
- can be caused by viruses, and less commonly by bacteria, fungi and protozoa
- is often more severe in allergic patients especially if infection occurs at the time of allergen exposure
- treatment that addresses only the acute problem may result in incomplete resolution of the infection or a later recurrence
- Since the mucosa of the the nose and sinuses is continuous, rhinitis should be called rhinosinusitis
Diagnosis
- Take a history
- Nasal examination:
- external and internal appearance
- secretions (clear, discoloured, blood stained)
- airflow
- palpation
- Skin prick testing is safe, inexpensive and helps the clinician to identify an allergic trigger, as well as graphically demonstrating the problem to the patient. Consider:
- RAST/specific IgE
- blood tests, e.g. FBC, thyroid function
See chart below
Classification of rhinits
ALLERGIC | INFECTIVE | OTHER | PART OF SYSTEMIC DISORDER |
|
|
|
|
INS=intranasal corticosteroids; SPT=skin prick test; RAST=radioallergosorbent test; QoL=Quality of Life; NSAID=non-steroidal anti-inflammatory drugs. Reproduced with kind permission from BSACI; http://www.bsaci.org
Treatment
Education
- The patient or carers should be informed about the potential impact of symptoms on sleep, work/school performance and the need for regular, prophylactic treatment
- Evidence-based education on effective forms of allergen avoidance and drug therapy, including safety and potential side effects, should be provided
- Treatment failure may be associated with poor compliance or with poor technique in the use of nasal sprays and drops, therefore appropriate training is imperative
Pharmacotherapy
- Despite allergen and trigger avoidance, many rhinitis sufferers continue to have persistent symptoms, the nature of which should determine the selection of medication
- Regular prophylactic medication, even in the absence of symptoms, is important
- Oral and topical antihistamines:
- place in therapy:
- first-line therapy for mild to moderate intermittent and mild persistent rhinitis
- additional to intranasal steroids for moderate/severe persistent rhinitis uncontrolled on topical INS alone
- place in therapy:
- Oral H1-antihistamines:
- effective predominantly on neurally mediated symptoms of itch, sneeze and rhinorrhoea
- improve allergic symptoms at sites other than the nose such as the conjunctiva, palate, skin and lower airways
- regular therapy is more effective than ‘as-needed’ use in persistent rhinitis
- Topical nasal H1-antihistamines (e.g. azelastine):
- fast onset of action within 15 min, useful as rescue therapy
- does not improve symptoms due to histamine at other sites, such as the eye, pharynx, lower airways and skin
- Topical intranasal corticosteroids (INS):
- place in therapy:
- first-line therapy for moderate to severe persistent symptoms and treatment failures with antihistamines alone
- topical steroid drops should be used initially in nasal polyposis and severe obstruction
- onset of action is 6–8 hours after the first dose, clinical improvement may not be apparent for a few days and maximal effect may not be apparent until after 2 weeks
- starting treatment 2 weeks before a known allergen season improves efficacy
- similar clinical efficacy for all INS but bioavailability varies considerably
- systemic absorption negligible with mometasone and fluticasone, modest for the remainder and high for betamethasone and dexamethasone – these should be used short term only
- long-term growth studies in children using fluticasone, mometasone and budesonide have reassuring safety data, unlike beclomethasone
- concomitant treatment with CYP3A inhibitors such as itraconazole or ritonivir may increase systemic bioavailability of INS
- raised intra-ocular pressure has been described with INS, patients with a history of glaucoma should be monitored more closely
- place in therapy:
- Systemic glucocorticosteroids:
- rarely indicated in the management of rhinitis, except for:
- severe nasal obstruction
- short-term (25 mg/day for 7 days) rescue medication for uncontrolled symptoms on conventional pharmacotherapy
- important social or work-related events, e.g. examinations, weddings
- oral corticosteroids should be used briefly and always in combination with a topical nasal corticosteroid
- rarely indicated in the management of rhinitis, except for:
- Anti-leukotrienes:
- place in therapy:
- montelukast is licensed in the UK for those with seasonal allergic rhinitis who also have concomitant asthma (UK license for age >6 months; zafirlukast UK license >12 years)
- may be useful in patients with asthma and persistent rhinitis
- place in therapy:
- Topical anti-cholinergic (e.g. ipratropium bromide):
- place in therapy:
- in ‘old man’s drip’
- as an ‘add on’ for allergic rhinitis when watery rhinorrhoea persists despite topical steroids and antihistamines
- for autonomic rhinitis when the dominant symptom is profuse watery rhinorrhoea in response to irritant triggers or changes in temperature
- decreases rhinorrhoea but has no effect on other nasal symptoms
- needs to be used three times daily, and titrate dose according to response
- also useful in the common cold
- place in therapy:
- Chromones (e.g. sodium cromoglicate):
- place in therapy:
- children and adults with mild symptoms only and sporadic problems in season or on limited exposure
- cromoglicate and nedocromil eyedrops are useful in conjunctivitis as topical therapy
- place in therapy:
- Treatment failure should always provoke a review of compliance
- • If regular treatment has been unsuccessful, the diagnosis should be reviewed and the need for alternative treatment (e.g. surgery) should reassessed
Immunotherapy (desensitisation)
- For pollen-allergic patients who fail to respond sufficiently to conventional treatment
Treatment of rhinitis
*Check nasal inhalation technique and complianceINS=intranasal corticosteroids; SPT=skin prick test; RAST=radioallergosorbent test; QoL=Quality of Life; NSAID=non-steroidal anti-inflammatory drugs. Reproduced with kind permission from BSACI; http://www.bsaci.org
Effect of therapies on rhinitis symptoms
Drug
| Sneezing | Rhinorrhoea | Nasal obstruction | Nasal itch | Eye symptoms |
H1-ANTIHISTAMINES | |||||
Oral
| ++ | ++ | + | +++ | ++ |
Intranasal
| ++ | ++ | + | ++ | 0 |
Eye drops
| 0 | 0 | 0 | 0 | +++ |
CORTICOSTEROIDS
| |||||
Intranasal
| +++ | +++ | +++ | ++ | ++ |
CHROMONES
| |||||
Intranasal
| + | + | + | + | 0 |
Eye drops
| 0 | 0 | 0 | 0 | ++ |
DECONGESTANTS
| |||||
Intranasal
| 0 | 0 | ++++ | 0 | 0 |
Oral
| 0 | 0 | + | 0 | 0 |
OT HER DRUGS
| |||||
Anti-cholinergics
| 0 | ++ | 0 | 0 | 0 |
Anti-cholinergics
| 0 | + | ++ | 0 | ++ |
Referral
- ENT referral is needed for:
- unilateral nasal problems
- nasal perforations, ulceration or collapse
- blood-stained discharge
- crusting high in the nasal cavity
- recurrent infection
- periorbital cellulitis (refer urgently)
- Allergy clinic referral is needed for:
- inadequate control of symptoms
- allergen/trigger identification
- to consider desensitisation
- recurrent nasal polyps
- multisystem allergy (e.g. rhinitis with asthma, eczema or food allergy)
- occupational rhinitis
Asthma and rhinitis
- Asthma and rhinitis usually co-exist, with symptoms of rhinitis found in 75–80% of patients with asthma
- Rhinitis is a risk factor for the development of asthma
- Treatment of rhinitis is associated with benefits for asthma
Rhinitis in pregnancy
- Rhinitis affects at least 20% of pregnancies and can start during any gestational week
- Informing the patient that pregnancy-induced rhinitis is a self-limiting condition is often reassuring
- Regular nasal douching may be helpful
- Most medications cross the placenta, and should only be prescribed when the apparent benefit is greater than the risk to the foetus
- It is a good practice to start treatment with ‘tried and tested’ drugs
- beclomethasone, fluticasone and budesonide appear to have good safety records as they are widely used in pregnant asthmatic women
- cromoglicate may be helpful
- chlorphenamine, loratidine and cetirizine may be added cautiously if additional treatment is needed but decongestants should be avoided
- Some antihistamines may increase the risk of spontaneous abortion or congenital malformation
- Topical corticosteroids have shown no evidence of harmful effects
I didn't know rhinitis affected 20% of pregnancies. I guess that's why it's important to get regular check ups during a pregnancy. It's interesting that rhinitis has many of the same symptoms as allergies. http://www.nwasthma.com/patient-education/sinus-disease/
ReplyDeleteI started on COPD Herbal treatment from Ultimate Health Home, the treatment worked incredibly for my lungs condition. I used the herbal treatment for almost 4 months, it reversed my COPD. My severe shortness of breath, dry cough, chest tightness gradually disappeared. Reach Ultimate Health Home via their email at ultimatehealthhome@gmail.com . I can breath much better and It feels comfortable!
ReplyDelete